메뉴 건너뛰기




Volumn 112, Issue 6, 2008, Pages 1288-1295

Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase 2 trial of the minnie pearl cancer research network

Author keywords

Alemtuzumab; Chronic lymphocytic leukemia; Fludarabine; Rituximab; Small lymphocytic lymphoma

Indexed keywords

ALEMTUZUMAB; ALLOPURINOL; CIMETIDINE; COTRIMOXAZOLE; DIPHENHYDRAMINE; FAMCICLOVIR; FLUDARABINE; PARACETAMOL; PETHIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

EID: 41149101075     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23271     Document Type: Article
Times cited : (34)

References (18)
  • 1
    • 23044510136 scopus 로고    scopus 로고
    • Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
    • Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079-4088.
    • (2005) J Clin Oncol , vol.23 , pp. 4079-4088
    • Keating, M.J.1    O'Brien, S.2    Albitar, M.3
  • 2
    • 19944429446 scopus 로고    scopus 로고
    • Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparison analysis of CALGB9712 and CALGB9011
    • Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparison analysis of CALGB9712 and CALGB9011. Blood. 2005;105:49-53.
    • (2005) Blood , vol.105 , pp. 49-53
    • Byrd, J.C.1    Rai, K.2    Peterson, B.L.3
  • 3
    • 0037106502 scopus 로고    scopus 로고
    • Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine
    • Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002;20:3891-3897.
    • (2002) J Clin Oncol , vol.20 , pp. 3891-3897
    • Rai, K.R.1    Freter, C.E.2    Mercier, R.J.3
  • 4
    • 21144456107 scopus 로고    scopus 로고
    • Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival
    • Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005;23:2971-2979.
    • (2005) J Clin Oncol , vol.23 , pp. 2971-2979
    • Moreton, P.1    Kennedy, B.2    Lucas, G.3
  • 5
    • 0031757274 scopus 로고    scopus 로고
    • CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study
    • Ludin J, Osterborg A, Brittinger G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. J Clin Oncol. 1998;16:3257-3263.
    • (1998) J Clin Oncol , vol.16 , pp. 3257-3263
    • Ludin, J.1    Osterborg, A.2    Brittinger, G.3
  • 6
    • 0344236261 scopus 로고    scopus 로고
    • Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia
    • O'Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 2003;98:2657-2663.
    • (2003) Cancer , vol.98 , pp. 2657-2663
    • O'Brien, S.M.1    Kantarjian, H.M.2    Thomas, D.A.3
  • 7
    • 1942442044 scopus 로고    scopus 로고
    • Alemtuzumab for minimal residual disease in CLL
    • Abstract 371
    • O'Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab for minimal residual disease in CLL. Blood. 2003;102:109a. Abstract 371.
    • (2003) Blood , vol.102
    • O'Brien, S.M.1    Kantarjian, H.M.2    Thomas, D.A.3
  • 8
    • 14944343819 scopus 로고    scopus 로고
    • Rituximab plus short duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network
    • Hainsworth JD, Litchy S, Morrissey LH, et al. Rituximab plus short duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005;23:1500-1506.
    • (2005) J Clin Oncol , vol.23 , pp. 1500-1506
    • Hainsworth, J.D.1    Litchy, S.2    Morrissey, L.H.3
  • 9
    • 0029981025 scopus 로고    scopus 로고
    • National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
    • Cheson BD, Bennett JA, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
    • (1996) Blood , vol.87 , pp. 4990-4997
    • Cheson, B.D.1    Bennett, J.A.2    Grever, M.3
  • 10
    • 0042449063 scopus 로고    scopus 로고
    • Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma
    • Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:1244-1255.
    • (1999) J Clin Oncol , vol.17 , pp. 1244-1255
    • Cheson, B.D.1    Horning, S.J.2    Coiffier, B.3
  • 11
    • 33845382806 scopus 로고
    • Non-parametric estimation from incomplete observations
    • Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
    • (1958) J Am Stat Assoc , vol.53 , pp. 457-481
    • Kaplan, E.L.1    Meier, P.2
  • 12
    • 33751009390 scopus 로고    scopus 로고
    • Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia
    • Fiegl M, Falkner A, Hopfinger G, et al. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia. Cancer. 2006;107:2408-2416.
    • (2006) Cancer , vol.107 , pp. 2408-2416
    • Fiegl, M.1    Falkner, A.2    Hopfinger, G.3
  • 13
    • 33744793781 scopus 로고    scopus 로고
    • Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia
    • Montillo M, Tedeschi A, Miqueleiz S, et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol. 2006;24:2337-2342.
    • (2006) J Clin Oncol , vol.24 , pp. 2337-2342
    • Montillo, M.1    Tedeschi, A.2    Miqueleiz, S.3
  • 14
    • 38049002872 scopus 로고    scopus 로고
    • Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukemia in first remission - long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)
    • Abstract 33
    • Schweighofer C, Ritgen M, Eichhorst B, et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukemia in first remission - long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Blood. 2006;108:14a. Abstract 33.
    • (2006) Blood , vol.108
    • Schweighofer, C.1    Ritgen, M.2    Eichhorst, B.3
  • 15
    • 0036683449 scopus 로고    scopus 로고
    • Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
    • Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:768-773.
    • (2002) Blood , vol.100 , pp. 768-773
    • Lundin, J.1    Kimby, E.2    Bjorkholm, M.3
  • 16
    • 36448986964 scopus 로고    scopus 로고
    • Alemtuzumab (CAMPATH, MABCAMPATH) has superior progression-free survival vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL)
    • Abstract 301
    • Hillmen P, Skotnicki A, Robak T, et al. Alemtuzumab (CAMPATH, MABCAMPATH) has superior progression-free survival vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL). Blood. 2006;108:93a. Abstract 301.
    • (2006) Blood , vol.108
    • Hillmen, P.1    Skotnicki, A.2    Robak, T.3
  • 17
    • 0030897222 scopus 로고    scopus 로고
    • Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia
    • Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J Clin Oncol. 1997;15:1567-1574.
    • (1997) J Clin Oncol , vol.15 , pp. 1567-1574
    • Osterborg, A.1    Dyer, M.J.2    Bunjes, D.3
  • 18
    • 11144357657 scopus 로고    scopus 로고
    • Alemtuzimab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions
    • Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzimab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103:3278-3281.
    • (2004) Blood , vol.103 , pp. 3278-3281
    • Lozanski, G.1    Heerema, N.A.2    Flinn, I.W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.